Protocol Paper

Implementation of the Liberia National Community Health Assistant (NCHA) Program and Under-five Mortality: A study protocol

Dominik Jockers[5]*, Richard Ngafuan[6], Till Baernighausen[1,2,5], Albert Kessley[6], Emily E. White[6], Avi Kenny[7], John Kraemer[8], John Geedeh[9], Jeffrey Rozelle[6], Leah Holmes[6], Hawa Obaje[6], Sylvester Wheh[12], Jon Pederson[11], Mark J. Siedner[1,6,10], Savior Mendin[6], Marion Subah[6], Lisa R Hirschhorn[3,13]

[1] Africa Health Research Institute
[2] T.H. Chan Harvard School of Public Health
[3] Third Coast Center for AIDS Research
[4] Harvard Medical School
[5] Heidelberg University
[6] Last Mile Health
[7] University of Washington
[8] Georgetown University
[9] Grand Bassa County Health Team
[10] Massachusetts General Hospital
[11] Mikro
[12] Ministry of Health, Liberia
[13] Northwestern University
* email: dominik.jockers@uni-heidelberg.de

Abstract

Introduction

Between 2018 and 2022 the Liberian Government implemented the National Community Health Assistant (NCHA) program to improve provision of maternal and child health care to underserved rural areas of the country. Whereas the contributions of this and similar community health worker (CHW) based healthcare programs have been associated with improved process measures, the impact of a governmental CHW program at scale on child mortality has not been fully established.

Methods/Design

We will conduct a cluster sampled, community-based survey with landmark event calendars to retrospectively assess child births and deaths among all children born to women in the Grand Bassa District of Liberia. We will use a mixed effects discrete survival model, taking advantage of the staggered program implementation in Grand Bassa districts over a period of 4 years to compare rates of under-5 child mortality between the pre- and post-NCHA program implementation periods.

Discussion

This study will be the first to estimate the impact of the Liberian NCHA program on under-5 mortality.

Trial registration: clinicaltrials.gov NCT: NCT05123378

Keywords: Community Health Assistants, Community Health Worker, child diseases, under-5 mortality

Introduction

Under-5 mortality (U5M) has been reduced globally from 93 deaths per 1,000 live births in 1990 to 38 per 1,000 live births in 2019. Nevertheless, 1 in 13 children continue to die before their fifth birthday in sub-Saharan Africa. According to the World Health Organization, most of the deaths are due to preventable and treatable diseases (WHO, 2017).

Liberia ranks among the worst nations globally in child health outcomes, with U5M rate estimated at 93 per 1000 live births (Liberia Institute of Statistics and Geo-Information Services - LISGIS et al., 2021). Remote areas are facing the greatest burden of mortality because of poor access and utilization of health care services (Kentoffio et al., 2016). The primary causes of U5M in the region are malaria, diarrhea and acute respiratory infections (ARI) (Liu et al., 2015; Simen-Kapeu et al., 2021), which are all preventable and treatable with health interventions that are feasible for implementation in low-income countries (Jones et al., 2003).

Many countries have adopted integrated Community Case Management (iCCM) strategies to address the causes and reduce U5M. Community health workers (CHWs) are at the core of many iCCM strategies. They act within their local community and provide services such as treatment of uncomplicated childhood diseases and referring complicated cases to health facilities (Perry et al., 2014). iCCM interventions have been shown to reduce U5M due to an increased treatment of malaria, ARI and diarrhea (Baqui et al., 2002; Das et al., 2013; Delacollette et al., 1996; Nyqvist et al., 2019; Sazawal & Black, 2003; Theodoratou et al., 2010; Victora et al., 2000).

In June, 2016, the Liberian Ministry of Health (MOH) initiated a national professionalized, incentivized, and clinically supervised community health worker cadre known as Community Health Assistants (CHA). These CHAs are embedded within the public-sector health workforce, with the goal of extending the reach of the country's primary health care system to an estimated 1.2 million people through a standardized national community health model. The CHAs provide a package of health care services and epidemic surveillance within communities and households on an equitable basis.

Although numerous studies have demonstrated improvements in child outcomes with iCCM interventions, evidence around the effects of government-run, CHW-delivered healthcare on child mortality in rural areas of sub-Saharan Africa is limited. Our central hypothesis is that the National Community Health Assistant (NCHA) program in Liberia reduced U5M in rural Liberia. To test this hypothesis, we will conduct a large, population-representative survey across a major county in Liberia, and use a mixed effects discrete survival model to retrospectively compare mortality in the pre- and post-implementation periods in order to estimate the effect of the CHA program on U5M.

Method

Study setting and population

Data collection did start in Grand Bassa county in January 2022. The county encompasses an area of 7,936 square kilometers and had an estimated total population of 224,839 in 2008

(LISGIS, 2009). The target population of the NCHA are households in communities with a distance of more than 5 km from the nearest health facility. Based on a county-wide community GIS mapping exercise conducted by LMH immediately before program implementation, 1,733 communities were identified as remote, totaling 23,702 households and approximately 13,400 people and 20,900 children under the age of five years. The remote population is predominantly poor and levels of education are low. In Table A1 in the Appendix we show descriptive statistics for the study population. The study has been registered at clinicaltrials.gov [NCT: NCT05123378]. Approval for the study was obtained from the University of Liberia-Pacific Institute for Research and Evaluation Institutional Review Board (18th of November 2021, 18-11-140) and Advarra Institutional Review Board (25th of January 2021, Pro00048901), United States.

Community Health Worker Intervention

The Program

As part of the post-Ebola investment plan for building a resilient health system in Liberia 2015-2021, the MOH prioritized the establishment of a robust cadre of community health workers in remote communities that were situated more than 5 km from the nearest health facility. Through the NCHA program, members of remote communities select their CHA. Those selected by their communities have to fulfil eligibility requirements, including being permanent residents in the community, aged 18 to 50 years, possess basic writing and math skills, be physically and mentally fit and must be fluent in the dialect spoken in their community. Once selected, CHAs complete a standardized training curriculum in community health and surveillance, child health and maternal and neonatal health. Services are covering treatment of diarrhea, ARI, and malaria following iCCM protocols, as well as family planning and birth preparedness. Since 2020 COVID-education and -referral has also been included in the CHAs work. Everyone in the communities more than 5 km from the nearest health facility is eligible to use the program directly or indirectly. CHAs are compensated with a monthly cash incentive of US $70 for about 20 hours of work per week. Program implementation is preceded by community engagement activities, which involves obtaining the support and advice of community leaders.

Implementation

The Liberian NCHA program was initiated in a stepwise manner across the eight districts of Grand Bassa County by the government of Liberia beginning in March 2018. It is planned to conclude in June 2022 (Figure 1). We will take advantage of this staggered implementation to form a study design similar in structure to a stepped wedge cluster randomized trial. However, the order of implementation was not randomized; judged by the Liberian MOH districts with more need for health interventions were prioritized in the intervention roll out. The staggering of implementation was conducted for operational and logistical reasons, rather than to facilitate an evaluation.

[here: Figure_1_map]

Figure 1: National Community Health Assistant (NCHA) program implementation schedule in Grand Bassa, Liberia
Source: Dominik Jockers

Study design

Starting in January 2022, we will conduct a census to assess U5M among the children of all women who complete the survey. The study is registered at clinicaltrials.gov (NCT05123378).

Data collection

Impact Assessment Survey

In the 2022 impact assessment survey, we will collect data on births and child deaths from mothers aged 15 to 54 in all eight health districts of Grand Bassa (see Appendix Table A2). We will use a survey tool based on the validated Demographic and Health Survey (DHS) that includes a full birth history, as well as questions on socioeconomic status, education, and covariates that we expect to be associated with our endpoints. We will supplement this dataset with geographic and community-level covariates obtained through a separate district mapping process. Whenever possible, the survey will be conducted in Liberian English. If a respondent speaks only Bassa, a local dialect without a commonly used written form, the enumerator will do on-the-spot translation, which they will be trained to do. We will obtain death dates using the standard Demographic and Health Survey approach, augmented with recall-enhanced elicitation. For the recall-enhanced elicitation, mothers are asked to recall all their children death dates if occurred within the last four years. The same method has been applied in similar settings by Nyqvist et al. (2019). Anchoring methods with landmark events will be used in the questionnaire to foster the outcome documentation (Loftus & Marburger, 1983). We will use a calendar developed specific to Grand Bassa County, providing landmark events helping to clearly mark the reference period. Reluctance to report U5M is not expected to vary systematically by program implementation date.

Survey sample selection

The impact assessment survey will be a full census; all 1,733 remote target communities in Grand Bassa will be selected and all households within selected communities will be surveyed. Within each household the survey population will consist of all women of reproductive age who are at least 15 years old (15-54). We selected the sample size to power our analysis using a mixed effects discrete survival model based on the assumption of a 25% decrease in the hazard of U5M following program implementation (see power calculation below).

Statistical Analysis

The Liberian NCHA intervention and data collection will provide a panel data set for U5M at the community level, covering a time period from January 2018 till August 2022. To estimate program effects on U5M we will use a mixed effects discrete survival model.

Our primary outcome of interest will be U5M at the community level. Our primary exposure of interest will be period of observation, which will be divided into pre- and post-NCHA program implementation periods. Our model will account for the possibility of a time-varying treatment effect. Children will provide observation to the model from their date of birth or January 2018 (starting date of the panel), whichever is later, until their death, fifth birthday or date of the survey in 2022. Children born before implementation who remain under observation at the implementation date in their community will provide observation time to both the pre- and post-observation time periods. We will fit a mixed effects discrete survival model with a random effect at the community level to estimate the relative risk of mortality between the pre- and post-implementation periods. To mitigate bias due to unobserved time-invariant confounders that were caused by the non-randomized implementation schedule of the program, we will

include a fixed effect at the district level. We will control for baseline demographic and geographic covariates at the community level.

Power Calculation

We chose to perform a full census of the district's 1,733 remote communities based on a set of simulation-based power calculations. Briefly, this involved simulating the population of eligible women (including their complete birth histories), taking a complex sample from this population, and running the planned statistical analysis on this sample. This entire procedure was performed repeatedly, and power was estimated as the percentage of simulation replicates for which the null hypothesis was rejected. Power was estimated as 82% for a full census. The treatment effect was assumed to be a 25% decrease in the hazard of U5M, linearly decreasing from the start of the program to six months and constant thereafter. The baseline mortality rate was set at roughly 100 deaths per 1,000 live births. The simulated dataset included random intercepts at the level of the community and at the level of the community-treatment interaction, allowing for heterogeneity in terms of both the baseline mortality rate and the effectiveness of the intervention.

Discussion

This study will estimate the impact of Liberian NCHA program including iCCM and perinatal care support in remote Liberia on U5M. The staggered implementation of scale up within Grand Bassa offers a unique opportunity to evaluate the effectiveness of this program on a population scale. The analysis will allow us to evaluate the implementation of a critical healthcare delivery program by the Liberian Ministry of Health on U5M within the target communities.

There are multiple unique aspects of this study which will enhance both its scope and generalizability. The total population census with a program coverage of 1.753 communities and 23,702 households in the Grand Bassa county of Liberia, we will take advantage of a notably large sample size. The fact that the NCHA program is being implemented staggered across eight study health districts in four phases also gives us the opportunity to apply mixed effects discrete survival model with a random effect by community and district fixed effects to compare the intervention effect both within and between geographic regions. Finally, the use of U5M as the primary outcome, as opposed to intermediate health care delivery indicators and process measures, will allow us to measure the population level impacts of such a CHW-based child health care program at scale.

There are limitations to the design of this study. First, the order of implementation by district was non-randomized. Because the districts with the worst health outcomes were targeted by the intervention first, our estimate of the intervention effect estimate may be biased. Nonetheless, the stepped approach to implementation, availability of pre- and post-implementation data in the districts, and our use of district fixed effects and community covariates all enhance the causal inference of this study design. Second, the random effects at the community level rely on an assumption of minimal correlation of unobserved confounders with NCHA program exposure. Third, the data for our outcome relies on endline survey data, thus selective migration by intervention implementation date potentially causes bias in the main estimates. To address this, we will include a sensitivity analysis that limits the analysis only to those mothers who report living in the implementation area for the full study

period. Third, U5M is assessed in the survey design by recall of such events in the last four years. There may be bias associated with mothers not remembering the correct birth/death dates of children. We will assume that this recall bias (and related biases, e.g. mothers' reluctance to discuss child deaths) is minimal and does not differ significantly by geography or intervention status date. To mitigate to this source of bias and increase the validity of death reporting, we will employ a landmark event calendar, which has been previously shown to improve precision of event reporting (Loftus & Marburger, 1983). Finally, the fidelity of implementation is not a component of this impact study, but is the focus of ongoing program evaluation to measure dose, coverage and effect of contextual factors including health facility readiness and the COVID-19 pandemic.

Prior studies have demonstrated improvement in process measures from implementation of small scale governmental CHW programs in similar settings including Liberia (Fiori et al., 2021; White et al., 2018). Whereas Nyqvist et al. (2019) were able to randomize program exposure across communities, the program was different from our evaluation in that it is was operated by a non-governmental organization. Our study will add to the literature by providing evidence from a large scale, governmental-led CHW program.

In summary, this study will provide invaluable insight on the impact of large-scale, publicly operated CHW programs on child health. Results will be directly applicable both to the Liberian Ministry of Health, as well as to other governmental entities supporting similar CHW-based rural child health programs in the region. Because such rural areas are known to face the largest U5M burden in many sub-Saharan countries, our study results will directly respond to the need to understand the optimal methods of improving health care among many of the most vulnerable populations in the region.

Abbreviations

acute respiratory infections = ARI; integrated Community Case Management = iCCM; Community Health Assistants = CHA; community health worker = CHW; Demographic and Health Survey = DHS; Ministry of Health = MOH; National Community Health Assistant = NCHA; Under-5 mortality = U5M.

Declarations

Ethics approval and consent to participate

Approval for the surveys was obtained from the University of Liberia-Pacific Institute for Research and Evaluation Institutional Review Board (18-11-140) and Advarra Institutional Review Board (Pro00048901), United States. All participants gave [verbal/written] informed consent to participate. Written informed consent was obtained from a parent or guardian for participants under 16 years old.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

The research is funded by Cargill, USAID DIV and UBS Optimus Foundation. The funders have no role in the study design, data collection, management, manuscript writing or decision to submit the report for publication.

Authors' contributions

LH is Principal Investigator (PI) and responsible for overall conceptualization of study design. MS is Partner PIs and responsible for design and implementation in Grand Bassa, Liberia. DJ led the drafting of the manuscript. AK, JK, and MJS contributed to conceptualization and study design. AK, JK, MJS, TB and DJ were responsible for statistical method development. AK provided the power calculation. EW, AK, JK, LH, HO, JP and MS provided technical input. RN, AK, JG, SW and SM contributed with local context expertise; HO coordinated between contributors. All authors reviewed a draft and read and approved the final manuscript.

Acknowledgements

Not Applicable

Supporting Information

Document 1: Appendix
Document 2: SPIRIT checklist

References

Baqui, A. H., Black, R. E., El Arifeen, S., Yunus, M., Chakraborty, J., Ahmed, S., & Vaughan, J. P. (2002). Effect of zinc supplementation started during diarrhoea on morbidity and mortality in Bangladeshi children: community randomised trial. *BMJ, 325*(7372), 1059. doi:10.1136/bmj.325.7372.1059

Das, J. K., Lassi, Z. S., Salam, R. A., & Bhutta, Z. A. (2013). Effect of community based interventions on childhood diarrhea and pneumonia: uptake of treatment modalities and impact on mortality. *BMC Public Health, 13*(Suppl 3), S29. doi:10.1186/1471-2458-13-S3-S29

Delacollette, C., Van der Stuyft, P., & Molima, K. (1996). Using community health workers for malaria control: experience in Zaire. *Bull World Heal Organ., 74*(4), 423–430.

Fiori, K. P., Lauria, M. E., Singer, A. W., Jones, H. E., Belli, H. M., Aylward, P. T., . . . Hirschhorn, L. R. (2021). An Integrated Primary Care Initiative for Child Health in Northern Togo. *Pediatrics, 148*(3). doi:10.1542/peds.2020-035493

Jones, G., Steketee, R. W., Black, R. E., Bhutta, Z. A., & Morris, S. S. (2003). How many child deaths can we prevent this year? *The Lancet, 362*(9377), 65-71. doi:10.1016/s0140-6736(03)13811-1

Kentoffio, K., Kraemer, J. D., Griffiths, T., Kenny, A., Panjabi, R., Sechler, G. A., . . . Siedner, M. J. (2016). Charting health system reconstruction in post-war Liberia: a comparison of rural vs. remote healthcare utilization. *BMC Health Serv Res, 16*, 478. doi:10.1186/s12913-016-1709-7

Liberia Institute of Statistics and Geo-Information Services - LISGIS, Minsitry of Health - MOH, & ICF. (2021). *Liberia Demographic and Health Survey 2019-20*. Retrieved from Monrovia, Liberia: https://www.dhsprogram.com/pubs/pdf/FR362/FR362.pdf

LISGIS. (2009). *2008 Population and Housing Census: Final Results*. Monrovia, Liberia: Liberia Institute of Statistics and Geo-Information Services (LISGIS).

Liu, L., Oza, S., Hogan, D., Perin, J., Rudan, I., Lawn, J. E., . . . Black, R. E. (2015). Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. *Lancet, 385*(9966), 430-440. doi:10.1016/S0140-6736(14)61698-6

Loftus, E. F., & Marburger, W. (1983). Since the eruption of Mt. St. Helens, has anyone beaten you up? Improving the accuracy of retrospective reports with landmarkevents. *Memory & Cognition, 11*(2), 114-120.

Nyqvist, M. B., Guariso, A., Svensson, J., & Yanagizawa-Drott, D. (2019). Reducing Child Mortality in the Last Mile: Experimental Evidence on Community Health Promoters in Uganda. *American Economic Journal: Applied Economics, 11*(3), 155-192. doi:10.1257/app.20170201

Perry, H. B., Zulliger, R., & Rogers, M. M. (2014). Community health workers in low-, middle-, and high-income countries: an overview of their history, recent evolution, and current effectiveness. *Annu Rev Public Health, 35*, 399-421. doi:10.1146/annurev-publhealth-032013-182354

Sazawal, S., & Black, R. E. (2003). Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a meta-analysis of community-based trials. *Lancet Infect Dis, 3*(9), 547-556. doi:10.1016/s1473-3099(03)00737-0

Simen-Kapeu, A., Bogler, L., Weber, A. C., Ntambi, J., Zagre, N. M., Vollmer, S., & Ekpini, R. E. (2021). Prevalence of diarrhoea, acute respiratory infections, and malaria over time (1995-2017): A regional analysis of 23 countries in West and Central Africa. *J Glob Health, 11*, 13008. doi:10.7189/jogh.11.13008

Theodoratou, E., Al-Jilaihawi, S., Woodward, F., Ferguson, J., Jhass, A., Balliet, M., . . . Campbell, H. (2010). The effect of case management on childhood pneumonia

mortality in developing countries. *Int J Epidemiol, 39 Suppl 1*, i155-171. doi:10.1093/ije/dyq032

Victora, C. G., Bryce, J., Fontaine, O., & Monasch, R. (2000). Reducing deaths from diarrhoea through oral rehydration therapy. *Bull World Health Organ., 8*(10), 1246–1255.

White, E. E., Downey, J., Sathananthan, V., Kanjee, Z., Kenny, A., Waters, A., . . . Kraemer, J. D. (2018). A Community Health Worker Intervention to Increase Childhood Disease Treatment Coverage in Rural Liberia: A Controlled Before-and-After Evaluation. *Am J Public Health, 108*(9), 1252-1259. doi:10.2105/AJPH.2018.304555

WHO. (2017). Children: Reducing Mortality. *WHO Fact Sheet.* Retrieved from https://www.who.int/en/news-room/fact-sheets/detail/children-reducing-mortality

Appendix

Table A1: Descriptive statistics remote Grand Bassa

	Remote Grand Bassa County
N Communities	1,733
N Households	23,702
N Health facilities	34
Average distance (remote community)	13.5 km

Households	
1st and 2nd rural wealth index quintiles (DHS 2013)	70%
No toilet facility	88%
Access to an improved non-shared toilet facility	2%
Access to an improved water source	22%

Women	
Attended some school	34%
Completed primary school	11%
Married or cohabitating	78%
Bassa language	60%
Antenatal care visits (> 3)	63%
Postnatal care visits within 48 hours	37%
In facility delivery	53%

Children under 5		
Disease	Prevalence	Treated by a qualified provider
Diarrhea	50%	75%
Fever	54%	62%
ARI	28%	67%
Vaccination	Coverage	
BCG, Penta, OPV and Measles	21%	

Note: Data covers all communities more than 5 km from the nearest health facility based on 2018 Last Mile Health's Grand Bassa household survey. ARI = acute respiratory infections, BCG = Bacillus Calmette–Guérin, OPV = Oral polio vaccine.

Table A2: Staggered treatment implementation and under-5 mortality measurement



Legend:	
CHA's begin training	
CHA's begin diagnosis and treatment of childhood illness	
LMH Survey	
Captured birth/death history in Endline survey	


Campwood
District #3 (C)
District #1
District #2
District #3 (A, B)
Owensgrove
Commonwealth
District #4
Atlantic Ocean
0
10
20 km
Hospital
Health Facility
Road
NCHA implementation
September 2018
February 2019
March 2021
October 2021
June 2022

Figure

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description
Administrative information		
Title (Page 1, title)	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
Trial registration (Page 2+4, Trial registration)	2a	Trial identifier and registry name. If not yet registered, name of intended registry
(N/A)	2b	All items from the World Health Organization Trial Registration Data Set
Protocol version (Page 1, Issue Date; Protocol Amendment Number)	3	Date and version identifier
Funding (Page 9, Funding)	4	Sources and types of financial, material, and other support
Roles and responsibilities (Page 1 and Page 9, Authors' contributions)	5a	Names, affiliations, and roles of protocol contributors
(Page 9, Funding)	5b	Name and contact information for the trial sponsor
(Page 9, Funding)	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
(N/A)	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
Introduction		

Background and rationale (Page 3, Background)	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
(N/A)	6b	Explanation for choice of comparators
Objectives (Page 3, Background)	7	Specific objectives or hypotheses
Trial design (Page 6, Statistical Analysis)	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
Methods: Participants, interventions, and outcomes		
Study setting (Page 3, Study Setting)	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
Eligibility criteria (Page 6, Survey Sample Selection)	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
Interventions (Page 4, The Program)	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
(N/A)	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
(N/A)	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
(N/A)	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
Outcomes (Page 6, Statistical Analysis)	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

Participant timeline (Page 12, Table 1)	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
Sample size (Page 6, Power Calculation)	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
Recruitment (Page 6, Survey sample selection)	15	Strategies for achieving adequate participant enrolment to reach target sample size
Methods: Assignment of interventions (for controlled trials)		
Allocation:		
Sequence generation (Page 4, Implementation)	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
Allocation concealment mechanism (Page 4, Implementation)	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
Implementation (Page 4, Implementation)	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions
Blinding (masking) (N/A)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how
(N/A)	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial
Methods: Data collection, management, and analysis		
Data collection methods (Page 5, Impact Assessment Survey)	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

(Page 5, Impact Assessment Survey)	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
Data management (N/A)	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
Statistical methods (Page 6, Statistical analysis)	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
(N/A)	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)
(Page 6, Survey sample selection)	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)
Methods: Monitoring		
Data monitoring (N/A)	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
(N/A)	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
Harms (N/A)	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
Auditing (N/A)	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
Ethics and dissemination		
Research ethics approval (Page 4+9, Ethics approval and consent to participate)	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval

Protocol amendments (N/A)	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
Consent or assent (N/A)	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
(N/A)	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
Confidentiality (N/A)	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
Declaration of interests (Page 9, Competing interests)	28	Financial and other competing interests for principal investigators for the overall trial and each study site
Access to data (Page 9, Availability of data and materials)	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
Ancillary and post-trial care (N/A)	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
Dissemination policy (N/A)	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
(Page 9, Authors' contributions)	31b	Authorship eligibility guidelines and any intended use of professional writers
(N/A)	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code
Appendices		
Informed consent materials (Attached)	32	Model consent form and other related documentation given to participants and authorised surrogates
Biological specimens (N/A)	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the

protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license.